Unknown

Dataset Information

0

Allogeneic CAR-T Cells: More than Ease of Access?


ABSTRACT: Patient derived anti-CD19 chimeric antigen receptor-T (CAR-T) cells are a powerful tool in achieving a complete remission in a range of B-cell malignancies, most notably B-acute lymphoblastic leukaemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). However, there are limitations, including inability to manufacture CAR-T cells from the patient's own T cells, disease progression and death prior to return of engineered cells. T cell dysfunction is known to occur in cancer patients, and several groups have recently described differences in CAR-T cells generated from chronic lymphocytic leukaemia (CLL) patients compared with those from a healthy donor. This is thought to contribute to the low response rate in this disease group. Healthy donor, gene-edited CAR-T cells which do not require human leucocyte antigen (HLA) matching have the potential to provide an 'off the shelf' product, overcoming the manufacturing difficulties of producing CAR-T cells for each individual patient. They may also provide a more functional, potent product for malignancies such as CLL, where T cell dysfunction is common and frequently cannot be fully reversed during the manufacturing process. Here we review the potential benefits and obstacles for healthy donor, allogeneic CAR-T cells.

SUBMITTER: Graham C 

PROVIDER: S-EPMC6210057 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Allogeneic CAR-T Cells: More than Ease of Access?

Graham Charlotte C   Jozwik Agnieszka A   Pepper Andrea A   Benjamin Reuben R  

Cells 20181001 10


Patient derived anti-CD19 chimeric antigen receptor-T (CAR-T) cells are a powerful tool in achieving a complete remission in a range of B-cell malignancies, most notably B-acute lymphoblastic leukaemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). However, there are limitations, including inability to manufacture CAR-T cells from the patient's own T cells, disease progression and death prior to return of engineered cells. T cell dysfunction is known to occur in cancer patients, and several  ...[more]

Similar Datasets

| S-EPMC7821739 | biostudies-literature
| S-EPMC4636084 | biostudies-literature
| S-EPMC7727575 | biostudies-literature
| S-EPMC7966522 | biostudies-literature
| S-EPMC9050731 | biostudies-literature
| S-EPMC10937087 | biostudies-literature
| S-EPMC4817890 | biostudies-other
| S-EPMC5383629 | biostudies-literature
| S-EPMC3747846 | biostudies-literature
2024-03-07 | GSE239648 | GEO